·Category 1 new drug ·Winner of the "China Patent Gold Award" ·The first anti-angiogenic drug approved in China for the third-line treatment of advanced non-small cell lung cancer ·Approved for 9 indications in China ·Included in 25 authoritative guidelines such as the "CSCO Clinical Practice Guidelines for Immune Checkpoint Inhibitors (2025 Edition)" and the "CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (2024 Edition)"

*For contraindications and adverse reactions, please see the package insert

·Anti-HER2 monoclonal antibody ·Covers three major indications: HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer ·Recommended by numerous domestic and international guidelines such as CSCO, CACA, and NCCN ·The Trastuzumab-Pertuzumab combination therapy is a standard treatment regimen commonly used in clinical practice for HER2-positive early-stage and advanced first-line metastatic breast cancer

*For contraindications and adverse reactions, please see the package insert

·Recombinant humanized IgG1 monoclonal antibody ·Used for multiple tumor types including colorectal cancer, lung cancer, and glioblastoma ·A cornerstone therapeutic drug unanimously recommended by multiple authoritative domestic and international guidelines such as NCCN and CSCO

*For contraindications and adverse reactions, please see the package insert

·Category 1 new drug ·The world's first long-acting leukocyte-elevating product based on a dimeric G-CSF-Fc fusion protein ·A new generation of long-acting granulocyte colony-stimulating factor (G-CSF) ·The first innovative G-CSF from China to be approved for marketing in China, the United States, and the European Union ·Currently the only domestic long-acting leukocyte-elevating injection included in the NCCN guidelines as a Category 2A recommendation

*For contraindications and adverse reactions, please see the package insert

Category 1 new drug ·An innovative humanized anti-PD-L1 monoclonal antibody with a novel sequence ·Combined with Anlotinib for the first-line treatment of patients with extensive-stage small cell lung cancer ·Supported by the National Science and Technology Major Project for "Innovative Drug Research and Development" ·Approved for 3 indications

*For contraindications and adverse reactions, please see the package insert

·Currently the world's only novel anti-PD-1 monoclonal antibody that uses an IgG1 subtype and has been optimized through Fc and Fab segment engineering ·Approved for 4 indications

*For contraindications and adverse reactions, please see the package insert

·Category 1 new drug ·The first domestically developed targeted drug for ROS1-positive non-small cell lung cancer ·Recommended by numerous authoritative guidelines such as the "Guiding Principles for Clinical Application of New Anti-tumor Drugs" by the National Health Commission and the "Clinical Diagnosis and Treatment Guidelines for Brain Metastases in Driver Gene-Positive Non-Small Cell Lung Cancer in China (2025 Edition)"

*For contraindications and adverse reactions, please see the package insert

·Category 1 new drug ·A new-generation ALK inhibitor developed independently ·Supported by the National Science and Technology Major Project for "Innovative Drug Research and Development" ·Significantly prolongs the progression-free survival in patients with ALK-positive advanced NSCLC

*For contraindications and adverse reactions, please see the package insert

·Category 1 new drug ·A domestic FIC & BIC targeted drug for KRAS G12C mutation, breaking the "undruggable" challenge ·Included and recommended by numerous authoritative guidelines such as the "Guiding Principles for Clinical Application of New Anti-tumor Drugs" by the National Health Commission and the "Clinical Diagnosis and Treatment Guidelines for Brain Metastases in Driver Gene-Positive Non-Small Cell Lung Cancer in China (2025 Edition)"

*For contraindications and adverse reactions, please see the package insert